MA37951B2 - Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium - Google Patents
Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésiumInfo
- Publication number
- MA37951B2 MA37951B2 MA37951A MA37951A MA37951B2 MA 37951 B2 MA37951 B2 MA 37951B2 MA 37951 A MA37951 A MA 37951A MA 37951 A MA37951 A MA 37951A MA 37951 B2 MA37951 B2 MA 37951B2
- Authority
- MA
- Morocco
- Prior art keywords
- irbesartane
- atorvastatin
- magnesium carbonate
- tablet formulation
- bilayer tablet
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005370 atorvastatin Drugs 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title abstract 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 title abstract 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 title abstract 2
- 239000001095 magnesium carbonate Substances 0.000 title abstract 2
- 239000007916 tablet composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120096477A KR20140028971A (ko) | 2012-08-31 | 2012-08-31 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| PCT/KR2013/007838 WO2014035188A1 (en) | 2012-08-31 | 2013-08-30 | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37951A1 MA37951A1 (fr) | 2018-06-29 |
| MA37951B2 true MA37951B2 (fr) | 2019-12-31 |
Family
ID=50183917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37951A MA37951B2 (fr) | 2012-08-31 | 2013-08-30 | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium |
Country Status (31)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6981088B2 (ja) * | 2017-01-27 | 2021-12-15 | ニプロ株式会社 | 経口固形製剤 |
| CN110913843B (zh) * | 2017-07-17 | 2022-09-13 | 伊莱利利公司 | 药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| PE20030324A1 (es) | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
| WO2009134076A2 (ko) * | 2008-04-29 | 2009-11-05 | 한올제약주식회사 | 방출성이 제어된 안지오텐신 - II - 수용체 차단제와 H M G - C o A 환원 효소 억제제의 복합제 조성물 |
| JP5534004B2 (ja) * | 2010-03-29 | 2014-06-25 | アステラス製薬株式会社 | 口腔内崩壊錠 |
| KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
-
2012
- 2012-08-31 KR KR1020120096477A patent/KR20140028971A/ko not_active Ceased
-
2013
- 2013-08-29 AR ARP130103083A patent/AR092386A1/es unknown
- 2013-08-30 NZ NZ706472A patent/NZ706472A/en not_active IP Right Cessation
- 2013-08-30 AU AU2013309686A patent/AU2013309686B2/en not_active Ceased
- 2013-08-30 UA UAA201502939A patent/UA115995C2/uk unknown
- 2013-08-30 JP JP2015529683A patent/JP6363079B2/ja not_active Expired - Fee Related
- 2013-08-30 US US14/421,467 patent/US20150209290A1/en not_active Abandoned
- 2013-08-30 TW TW102131243A patent/TWI651101B/zh not_active IP Right Cessation
- 2013-08-30 UY UY0001035001A patent/UY35001A/es not_active Application Discontinuation
- 2013-08-30 MX MX2015002526A patent/MX354800B/es active IP Right Grant
- 2013-08-30 IN IN1463DEN2015 patent/IN2015DN01463A/en unknown
- 2013-08-30 WO PCT/KR2013/007838 patent/WO2014035188A1/en not_active Ceased
- 2013-08-30 MA MA37951A patent/MA37951B2/fr unknown
- 2013-08-30 PE PE2015000220A patent/PE20150935A1/es not_active Application Discontinuation
- 2013-08-30 BR BR112015004471A patent/BR112015004471A8/pt not_active IP Right Cessation
- 2013-08-30 MY MYPI2015700489A patent/MY175897A/en unknown
- 2013-08-30 CN CN201380045377.2A patent/CN104602677A/zh active Pending
- 2013-08-30 EA EA201590469A patent/EA030306B1/ru not_active IP Right Cessation
- 2013-08-30 RU RU2015111546A patent/RU2015111546A/ru unknown
- 2013-08-30 SG SG11201500584YA patent/SG11201500584YA/en unknown
- 2013-08-30 CA CA2882735A patent/CA2882735A1/en not_active Abandoned
- 2013-08-30 EP EP13833700.1A patent/EP2890368A4/en not_active Withdrawn
-
2015
- 2015-02-19 CL CL2015000402A patent/CL2015000402A1/es unknown
- 2015-02-24 PH PH12015500394A patent/PH12015500394A1/en unknown
- 2015-02-25 IL IL237424A patent/IL237424A0/en unknown
- 2015-02-26 DO DO2015000040A patent/DOP2015000040A/es unknown
- 2015-02-26 GT GT201500043A patent/GT201500043A/es unknown
- 2015-02-27 NI NI201500027A patent/NI201500027A/es unknown
- 2015-03-05 CR CR20150115A patent/CR20150115A/es unknown
- 2015-03-20 EC ECIEPI201510600A patent/ECSP15010600A/es unknown
- 2015-03-30 ZA ZA2015/02156A patent/ZA201502156B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012024139A2 (pt) | formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide. | |
| CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
| CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
| EP2814939A4 (en) | NANOPORENSENSOR FOR ENZYME-EMITTED PROTEIN TRANSLATION | |
| EP2599471A4 (en) | Tablet splitting device | |
| IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
| NL1031503A1 (nl) | Stereoscopisch beeldscherm voor omschakelen tussen 2D/3D beelden. | |
| EA201690679A1 (ru) | Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан | |
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| EP3020717A4 (en) | P2x4 receptor antagonist | |
| FR3003747B1 (fr) | Systeme pour abouter deux vaisseaux sanguins. | |
| CY1110097T1 (el) | Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων | |
| UA107967C2 (en) | Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan | |
| SG11201510134YA (en) | Real-time multi-functional ecg signal processing system, dspe for the ecg signal processing system, and method thereof | |
| WO2015031778A3 (en) | Compositions and methods for the treatment or prevention of tuberculosis | |
| EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
| WO2014133744A3 (en) | Oral care compositions | |
| IT1397313B1 (it) | Unita' di taglio per macchina o pressa di termoforatura e macchina di termoforatura dotata di tale unita' di taglio. | |
| MA37951B2 (fr) | Formulation de comprimé composite bicouche comprenant de l'atorvastatine, de l'irbesartane et du carbonate de magnésium | |
| IN2015DN01018A (enExample) | ||
| EA201190282A1 (ru) | Фармацевтическая композиция, содержащая тамсулозин | |
| WO2019059868A3 (en) | PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ | |
| EA201301355A1 (ru) | Композиция и таблетка, содержащая ралтегравир | |
| WO2012016646A9 (de) | Quetiapin-tabletten | |
| WO2014133746A3 (en) | Oral care compositions |